Toxys Inc. is a biotechnology company based in New York, New York, specializing in in vitro toxicology services. Located at 228 E 45th Street, this company focuses on advanced testing methodologies that assess genotoxicity, developmental and reproductive toxicity (DART), and mechanistic toxicological profiles. By utilizing innovative New Approach Methodologies (NAMs), Toxys Inc. supports research and development efforts across various industries that require detailed safety and toxicity data.
The company’s offerings include specialized assays that contribute to understanding the potential adverse effects of chemicals and pharmaceuticals at a cellular and molecular level. These services are designed to provide precise, mechanistic insights into toxicological endpoints, aiding clients in regulatory compliance and risk assessment. Toxys Inc. integrates scientific rigor with technological advancements to offer reliable alternatives to traditional animal testing models.
Operating within the dynamic biotechnology sector of New York City, Toxys Inc. maintains a connection with research institutions in both the Netherlands and the United States. This international collaboration enriches its technological capabilities and broadens its scope in the global life sciences landscape. The company’s focus on cutting-edge in vitro testing reflects the growing demand for efficient and ethical toxicological evaluation methods.
Toxys Inc. plays a role in supporting safer product development by delivering detailed toxicological data to biotechnology firms, pharmaceutical companies, and regulatory bodies. Its expertise in the application of NAMs aligns with current trends in the industry toward more predictive and human-relevant testing strategies. As a biotechnology company, Toxys Inc. continues to contribute to the advancement of toxicology through innovation and scientific expertise.
